Depends on the market, and your strategy would depend on the type of product. For the "mature" agencies (FDA, HC, EMA) there should be no problem as long as your explain and justify your strategy.
We have successfully used bracketing for different fill volumes of a biological parenteral in the US at least. The main thing is to determine what aspects are different for the different strengths and the risks associated with those differences.
Some ROW countries have very specific requirements and bracketing can become more difficult. Though I've more often seen where bracketing for process validation was accepted but not for stability.
------------------------------
Rachel Thornton
Associate Director
Smyrna GA
United States
------------------------------
Original Message:
Sent: 17-Feb-2023 09:48
From: Valeria Shkuratova
Subject: Bracketing Validation Batches
Hi,
Assuming we have a drug product with 10 different strengths, can bracketing be used for process validation? I know bracketing can be used for stability but does it apply to validation as well?
If so what strategy should be used to select strengths that will be validated and consequently placed on stability?
Thank you
------------------------------
Valeria Shkuratova
Canada
------------------------------